Leuprolide vs Triptorelin

How they're alike

Leuprolide and triptorelin are both synthetic GnRH (LHRH) superagonists built on the same decapeptide scaffold as endogenous gonadotropin-releasing hormone, each carrying a D-amino-acid substitution at position 6 that confers peptidase resistance and dramatically extends plasma residence relative to native GnRH. Both target the GnRH receptor (GnRHR) on pituitary gonadotropes — a Gq/11-coupled GPCR whose continuous (rather than pulsatile) stimulation triggers receptor internalization, uncoupling from phospholipase C, and transcriptional downregulation, collapsing downstream LH and FSH output and producing castrate-level sex-hormone suppression within 3–4 weeks (Schally 2025). Both produce the same biphasic clinical signature: an initial 7–14 day testosterone or estrogen "flare," then sustained suppression for the duration of depot dosing. Both are delivered as PLGA-microsphere or polymer depot injections covering one to six months per administration, and both are first-line agents for androgen deprivation in advanced prostate cancer (Fontana 2021) and for hypothalamic-pituitary-gonadal suppression in central precocious puberty. Both are also used as pituitary-suppression backbones in IVF long protocols and have been explored across hormone-sensitive gynecologic disease, including endometriosis (Vannuccini 2022).

How they differ

Structurally the two diverge at position 6 and at the C-terminus. Leuprolide is a nonapeptide: D-Leu replaces Gly at position 6, the terminal Gly10 is deleted, and the C-terminus is capped as Pro-ethylamide. Triptorelin retains the full ten-residue backbone with D-Trp at position 6, a pyroglutamate at the N-terminus, and a C-terminal amide. Functionally, triptorelin has been characterized as roughly 13-fold more potent than native GnRH for LH release and 21-fold for FSH release (per its product information and the underlying pharmacology), with a free-form plasma half-life of approximately 3 hours; leuprolide is described in the same literature as a comparably high-potency superagonist (~80× native GnRH). Once converted to depot form, however, the kinetics that matter clinically are governed by the microsphere or polymer-implant matrix rather than the free-peptide half-life, and the steady-state suppression both agents achieve is essentially equivalent within the GnRH agonist class.

The most consequential difference is regulatory and historical breadth. Leuprolide was FDA-approved in April 1985 — making it one of the earliest peptide drugs in modern oncology — and its US label spans advanced prostate cancer, endometriosis, uterine fibroids (preoperative), and central precocious puberty. Triptorelin reached the US market 15 years later (Trelstar, June 2000) and only added a pediatric indication with Triptodur in June 2017; its US label is limited to advanced prostate cancer and central precocious puberty, although in the EU and other markets (as Decapeptyl, Diphereline, Gonapeptyl, Pamorelin) it carries the broader endometriosis, fibroid, IVF, and adjuvant ovarian-suppression indications that leuprolide holds in the US. The depot menu is correspondingly wider for leuprolide: 1-, 3-, 4-, and 6-month formulations across multiple brands, versus triptorelin's 1-, 3-, and 6-month options. As a result, leuprolide also dominates the comparator slot in landmark trials of newer agents, including the antagonist-comparison program (PRONOUNCE vs degarelix; HERO vs oral relugolix) and the combination-therapy program (EMBARK with enzalutamide); triptorelin's comparable head-to-head dataset against next-generation antagonists is more limited.

Head-to-head clinical evidence

Direct head-to-head trials of triptorelin versus leuprolide are concentrated in three clinical contexts. In advanced prostate cancer, a multicenter randomized comparison in BJU International (2003) examined triptorelin pamoate against leuprolide acetate on testosterone suppression and PSA endpoints, and a three-arm comparative study in Investigative and Clinical Urology (2019) evaluated goserelin, triptorelin, and leuprolide for chemical castration efficacy. A 1997 European Urology randomized comparison and a 2013 Urologic Nursing multicenter RCT on tolerability and adverse events further populate the prostate-cancer head-to-head literature. The pattern across these studies is class-equivalence — testosterone and PSA suppression do not segregate meaningfully between the two agonists, and selection in practice tracks formulation availability, depot interval, payer access, and clinician preference rather than efficacy.

In pediatric central precocious puberty, a Korean retrospective cohort in Annals of Pediatric Endocrinology & Metabolism (2025) compared 3-month depot leuprolide acetate (n=48) and triptorelin pamoate (n=21) in overweight and obese girls and reported no significant difference in LH suppression at 6 months (2.31±1.34 vs 1.95±1.45 IU/L; p=0.46) or in final-treatment height (148.95±6.52 vs 150.53±6.79 cm; p=0.53). A second 2025 series in Clinical and Experimental Pediatrics compared the same two agents on 3-month dosing for central precocious puberty. An earlier 2004 Journal of Pediatric Endocrinology & Metabolism comparative trial likewise assessed gonadotropin suppression and final height with the two analogs in girls with accelerated and slowly progressive forms of early puberty. Across pediatric studies the direction of effect is consistent: comparable LH suppression and comparable predicted adult height outcomes.

In assisted reproductive technology, a prospective randomized study in Fertility and Sterility (2002) compared leuprolide acetate and triptorelin in IVF long-protocol pituitary suppression and ovarian stimulation, finding the two functionally interchangeable as pituitary-suppression backbones — a result consistent with the broader IVF GnRH-agonist literature.

Safety profile comparison

The class-level adverse-event profile is the same for both agents and follows directly from sustained sex-hormone suppression: hot flashes, decreased libido, erectile dysfunction (in men), injection-site reactions, fatigue, mood changes, and over longer exposure progressive bone mineral density loss. Both labels flag the initial testosterone or estrogen flare during the first 7–14 days, which in high-tumor-burden prostate cancer can transiently worsen bone-metastasis pain, ureteral obstruction, or spinal-cord compression risk; both carry pregnancy contraindications, hypersensitivity warnings (with cross-reactivity possible between GnRH analogs), and class-level cautions for QT-interval prolongation. Cardiovascular and metabolic risk during prolonged androgen deprivation is recognized for the class as a whole, and the agonist-versus-antagonist cardiovascular question has been studied most extensively for leuprolide as the comparator arm (PRONOUNCE vs degarelix; HERO vs relugolix), where the PRONOUNCE primary cardiovascular endpoint was inconclusive and HERO sub-analyses generated subgroup signals favoring the antagonist; triptorelin-specific cardiovascular comparison data against next-generation antagonists are more limited. Neither agent has a uniquely distinguishing boxed warning that separates it from the other; the practical differences in safety experience tend to track depot interval, injection-site formulation, and duration of exposure rather than choice of agonist (Kawahara 2025).

Indication overview

Both leuprolide and triptorelin are FDA-approved for advanced prostate cancer and for central precocious puberty in pediatric patients. Leuprolide additionally holds FDA approvals for endometriosis (1990) and for preoperative management of uterine fibroids (1995); triptorelin's US label does not currently include these gynecologic indications, although they are approved internationally under the Decapeptyl, Diphereline, Gonapeptyl, and Pamorelin brand names. Leuprolide is also used as a pituitary-suppression backbone in IVF long protocols (and in dual-trigger oocyte-maturation strategies) and has been incorporated into combination androgen-blockade regimens with second-generation anti-androgens such as enzalutamide (EMBARK) and abiraterone in localized and biochemically recurrent disease. Triptorelin is used internationally for adjuvant ovarian suppression in premenopausal hormone-receptor-positive breast cancer in addition to its prostate-cancer and pediatric uses. Both agents are listed by WADA under S4 (Hormone and Metabolic Modulators) and prohibited in male athletes outside of approved therapeutic-use exemptions. Within the GnRH agonist class, the wider US regulatory footprint and longer real-world experience of leuprolide are reflected in its dominant role as the comparator in next-generation prostate-cancer trial design; triptorelin remains a well-established alternative with comparable suppression efficacy and a deep international indication base.